ArticleTherapeutic advances in neurological disorders2009
Therapy for Alzheimer's Disease: How Effective are Current Treatments?
Article in Therapeutic advances in neurological disorders, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effects of reality orientation therapy on activities of daily living and other clinical outcomes in dementia: a systematic review and meta-analysis.BMC geriatrics · 2026Pooled it
- Cholinesterase inhibitors for rarer dementias associated with neurological conditions.The Cochrane database of systematic reviews · 2015Pooled it
- Bilateral deep brain stimulation of the fornix for Alzheimer's disease: surgical safety in the ADvance trial.Journal of neurosurgery · 2016Trial
- Feasibility of identifying factors related to Alzheimer's disease and related dementia in real-world data.JAMIA open · 2026Review
- Article
- Risk of Antipsychotic Initiation Among Older Dementia Patients Initiating Cholinesterase Inhibitors.Drug, healthcare and patient safety · 2025Article
- Artificial intelligence assisted identification of potential tau aggregation inhibitors: ligand- and structure-based virtual screening, in silico ADME, and molecular dynamics study.Molecular diversity · 2024Article
- Review
- Potential Anti-Amnesic Activity of a Novel Multimodal Derivative of Salicylamide, JJGW08, in Mice.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Neuroprotective effect of ranolazine improves behavioral discrepancies in a rat model of scopolamine-induced dementia.Frontiers in neuroscience · 2023Article
- Review
- Therapeutic Potential of Human Stem Cell Implantation in Alzheimer's Disease.International journal of molecular sciences · 2021Review
- Role of Withaferin A and Its Derivatives in the Management of Alzheimer's Disease: Recent Trends and Future Perspectives.Molecules (Basel, Switzerland) · 2021Review
- Bay Leaf (Antioxidants (Basel, Switzerland) · 2021Article
- Atorvastatin Improves Mitochondrial Function and Prevents Oxidative Stress in Hippocampus Following Amyloid-βMolecular neurobiology · 2020Article
- mGluR5 Contribution to Neuropathology in Alzheimer Mice Is Disease Stage-Dependent.ACS pharmacology & translational science · 2020Article
- Olive Oil Polyphenols in Neurodegenerative Pathologies.Advances in experimental medicine and biology · 2020Review
- Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.Current Alzheimer research · 2020Article
- Neurotrophic Factors Mediated Activation of Astrocytes Ameliorate Memory Loss by Amyloid Clearance after Transplantation of Lineage Negative Stem Cells.Molecular neurobiology · 2019Article
- PQM130, a Novel Feruloyl-Donepezil Hybrid Compound, Effectively Ameliorates the Cognitive Impairments and Pathology in a Mouse Model of Alzheimer's Disease.Frontiers in pharmacology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Available symptomatic therapies for the treatment of Alzheimer's disease (AD) have been based on known neurotransmitter dysfunctions associated with the illness. The second-generation cholinesterase inhibitors and the N-methyl D-aspartate receptor antagonist memantine have been widely prescribed and studied. Meta-analyses of these therapies were reviewed, focusing on effectiveness and tolerability. Although many of the meta-analyses demonstrate statistically significant improvements, some question if these benefits are sufficient to justify their current widespread and protracted use. This has spurred the development of new disease-modifying therapies that aim to have a greater impact on this debilitating illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.